9月17日，10x Genomics盘中上涨5.57%，报76.445美元/股，成交额1577.87万美元。
消息面上，公司近期利好密集释放。瑞银大幅上调目标价自20美元至68美元，维持中性评级；RBC亦以70美元目标价启动覆盖。此外，公司宣布与医学AI公司Lunit达成战略合作，将其AI病理平台整合至肿瘤生物标志物发现工作流，推动空间分子数据与AI病理学融合。基本面方面，公司二季度每股亏损0.14美元，大幅优于市场预期的亏损0.24美元，营收1.51亿美元亦超预期，全年收入指引上调至6.1亿至6.3亿美元。
同板块中，Tempus AI涨9.23%，Illumina涨3.52%，赛默飞世尔涨0.88%，生命科学工具板块整体表现活跃。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.